IBRX实时信号 | 通过Getagraph.com最大化利润

购买 106831 min ago

@ $4.52

发出时间: 15 Feb 2024 @ 02:58

回报率: 62.79%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 4.24 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	39.08M
平均成交量	5.40M
市值	4.95B
EPS	$-0.350 ( 2024-03-20 )
下一个收益日期	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.117 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Simon Barry J.	Buy	159 146	Stock Option (right to buy)
2024-02-22	Simon Barry J.	Buy	45 731	Restricted Stock Units
2024-02-22	Lauer Regan J	Buy	42 439	Stock Option (right to buy)
2024-02-22	Lauer Regan J	Buy	12 195	Restricted Stock Units
2024-02-22	Sachs David C.	Buy	424 390	Stock Option (right to buy)

INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 \| Sell: 921 083

音量相关性

長: 0.53 (weak)

短: -0.15 (neutral)

Signal:(48.073) Neutral

ImmunityBio, Inc. 相关性

10 最正相关
SIRI	0.928
RGF	0.928
FGBI	0.925
AROW	0.921
ALRS	0.92
GNTY	0.92
CBNK	0.915
GSMG	0.914
GOOD	0.906
ALLK	0.906

10 最负相关
RIVE	-0.933
DSEY	-0.93
DUOL	-0.927
AMPH	-0.926
RAM	-0.919
INTA	-0.919
PLYA	-0.918
ALTR	-0.91
DAIO	-0.909
MLTX	-0.907

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ImmunityBio, Inc. 相关性 - 货币/商品

0.51
( weak )

0.64
( weak )

0.00
( neutral )

0.23
( neutral )

0.04
( neutral )

0.83
( strong )

ImmunityBio, Inc. 财务报表

Annual	2023
营收:	$622 000
毛利润:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2023
营收:	$622 000
毛利润:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2022
营收:	$240 000
毛利润:	$-23.95M (-9 980.00 %)
EPS:	$-1.040

FY	2021
营收:	$934 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.